Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF.
暂无分享,去创建一个
S. Libutti | M. Gnant | D. Bartlett | H. Alexander | M. Puhlmann | J. Friedl | Markus Puhlmann | H Richard Alexander | David L Bartlett | Steven K Libutti | Josef Friedl | Ewa N Turner | Michael F X Gnant | Ewa Turner | Michael F. X. Gnant
[1] M. Gnant,et al. Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells. , 2000, Cytokine.
[2] P. Schlag,et al. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas. , 1997, Seminars in oncology.
[3] H. Gerlach,et al. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas , 1988, The Journal of experimental medicine.
[4] T S Edgington,et al. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[5] M. Inbar,et al. High dose tumor necrosis factor‐α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation , 1997, Cancer.
[6] P. Carmeliet. Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.
[7] D. Fraker,et al. Isolated limb perfusion for malignant melanoma. , 1996, Seminars in surgical oncology.
[8] H. Gerlach,et al. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins , 1989, The Journal of experimental medicine.
[9] J. Kirkwood,et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. , 1995, The cancer journal from Scientific American.
[10] H. Alexander,et al. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] W. Kisiel,et al. Mechanism of the Tumor Necrosis Factor α-mediated Induction of Endothelial Tissue Factor (*) , 1995, The Journal of Biological Chemistry.
[12] H. Gerlach,et al. Enhanced responsiveness of endothelium in the growing/motile state to tumor necrosis factor/cachectin [published erratum appears in J Exp Med 1989 Nov 1;170(5):1793] , 1989, The Journal of experimental medicine.
[13] G. Bieler,et al. Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ , 1998, Nature Medicine.
[14] A. Eggermont,et al. Isolated limb perfusion in primary and recurrent melanoma: indications and results. , 1998, Seminars in surgical oncology.
[15] P. Schlag,et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.
[16] T Vernet,et al. Alteration of Endothelial Cell Monolayer Integrity Triggers Resynthesis of Vascular Endothelium Cadherin* , 1998, The Journal of Biological Chemistry.
[17] A. Eggermont,et al. Harly endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high‐dose tumour necrosis factor alpha (rTNFα) , 1994 .
[18] S. Libutti,et al. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). , 1999, Cancer research.
[19] D. Stern,et al. Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.
[20] D. Fraker,et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Fallon,et al. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[22] S. Sleijfer,et al. Effects of hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan on pulmonary function assessments. , 1997, Journal of immunotherapy.
[23] V. Devita,et al. Biologic Therapy of Cancer , 1992 .
[24] B. Feig. Isolated limb perfusion for extremity sarcoma , 2000, Current oncology reports.
[25] N. Renard,et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] T. Luther,et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. , 1994, The Journal of clinical investigation.
[27] D. Fraker,et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Chioléro,et al. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. , 1995, Chest.
[29] P. Neumann,et al. Protein kinase C-α mediates endothelial barrier dysfunction induced by TNF-α , 2000 .
[30] P. Flemming,et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. , 1998, Surgery.
[31] Donald W. Miller,et al. Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-alpha exposure. , 1999, Life sciences.
[32] A. Eggermont,et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.